EnGene Holdings ETF Leadership

ENGN Etf  USD 5.07  1.18  30.33%   
About 71 percent of all EnGene Holdings' insiders are acquiring. The analysis of the overall insider sentiment regarding enGene Holdings Common suggests that quite a few insiders are confidant. EnGene Holdings employs about 56 people. The company is managed by 17 executives with a total tenure of roughly 131 years, averaging almost 7.0 years of service per executive, having 3.29 employees per reported executive.
DSc FRSC  Founder
CoFounder Board
Joan Connolly  Executive
Chief Officer

Insider Sentiment 71

 Mostly Buying

 
Selling
 
Buying

Latest Trades

2024-10-07Growth Opportunities F ForbionAcquired 11844 @ 6.55View
2024-10-04Growth Opportunities F ForbionAcquired 5997 @ 6.54View
2024-10-02Growth Opportunities F ForbionAcquired 10153 @ 6.37View
2024-09-30Growth Opportunities F ForbionAcquired 341332 @ 6.34View
2024-09-27Ronald Harold Wilfred CooperAcquired 10000 @ 5.7View
2024-04-22De Solidarite Des Travai FondsDisposed 47854 @ 15View
2024-04-18De Solidarite Des Travai FondsDisposed 4575 @ 15.01View
Monitoring EnGene Holdings' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in enGene Holdings Common. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in price.

EnGene Holdings Management Team Effectiveness

The company has return on total asset (ROA) of (0.2575) % which means that it has lost $0.2575 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4421) %, meaning that it created substantial loss on money invested by shareholders. EnGene Holdings' management efficiency ratios could be used to measure how well EnGene Holdings manages its routine affairs as well as how well it operates its assets and liabilities.

EnGene Holdings Workforce Comparison

enGene Holdings Common is rated # 5 ETF in number of employees as compared to similar ETFs. The total workforce of Health Care category is currently estimated at about 7,672. EnGene Holdings maintains roughly 56.0 in number of employees contributing less than 1% to all ETFs under Health Care category.

EnGene Holdings Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific EnGene Holdings insiders, such as employees or executives, is commonly permitted as long as it does not rely on EnGene Holdings' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, EnGene Holdings insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Ronald Cooper over a month ago
Acquisition by Ronald Cooper of 850000 shares of EnGene Holdings at 7. subject to Rule 16b-3
 
Forbion Growth Opportunities Fund I Cooperatief U.a. over three months ago
Acquisition by Forbion Growth Opportunities Fund I Cooperatief U.a. of 5997 shares of EnGene Holdings at 6.5436 subject to Rule 16b-3
 
Forbion Growth Opportunities Fund I Cooperatief U.a. over three months ago
Acquisition by Forbion Growth Opportunities Fund I Cooperatief U.a. of 561797 shares of EnGene Holdings at 8.9 subject to Rule 16b-3
 
Forbion Growth Opportunities Fund I Cooperatief U.a. over three months ago
Acquisition by Forbion Growth Opportunities Fund I Cooperatief U.a. of 800 shares of EnGene Holdings at 6.5981 subject to Rule 16b-3
 
Forbion Growth Opportunities Fund I Cooperatief U.a. over three months ago
Acquisition by Forbion Growth Opportunities Fund I Cooperatief U.a. of 11844 shares of EnGene Holdings at 6.546 subject to Rule 16b-3
 
Forbion Growth Opportunities Fund I Cooperatief U.a. over three months ago
Acquisition by Forbion Growth Opportunities Fund I Cooperatief U.a. of 5997 shares of EnGene Holdings at 6.5436 subject to Rule 16b-3
 
Forbion Growth Opportunities Fund I Cooperatief U.a. over three months ago
Acquisition by Forbion Growth Opportunities Fund I Cooperatief U.a. of 10153 shares of EnGene Holdings at 6.3722 subject to Rule 16b-3
 
Forbion Growth Opportunities Fund I Cooperatief U.a. over three months ago
Acquisition by Forbion Growth Opportunities Fund I Cooperatief U.a. of 341332 shares of EnGene Holdings at 6.338 subject to Rule 16b-3

EnGene Holdings Notable Stakeholders

An EnGene Holdings stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as EnGene Holdings often face trade-offs trying to please all of them. EnGene Holdings' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting EnGene Holdings' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
DSc FRSCCoFounder BoardProfile
Anthony CheungCoFounder OfficerProfile
JD EsqCEO DirectorProfile
Alex NicholsPresident COOProfile
David DawsCFO DevelopmentProfile
Ronald CooperChief DirectorProfile
Paul EricksonNonExecutive DirectorProfile
Sharon TanVP ManagementProfile
Joan ConnollyChief OfficerProfile
Tara MBASenior ResourcesProfile
Raj MDChief OfficerProfile
Alexander NicholsChief OfficerProfile
Matthew BoydSenior AffairsProfile
Dr MScChief OfficerProfile
MBChB MFPMChief OfficerProfile
Lee GiguereChief SecretaryProfile
FACS MDChief OfficerProfile

About EnGene Holdings Management Performance

The success or failure of an entity such as enGene Holdings Common often depends on how effective the management is. EnGene Holdings management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of EnGene management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the EnGene management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
EnGene Holdings is entity of United States. It is traded as Etf on NASDAQ exchange.
The data published in EnGene Holdings' official financial statements typically reflect EnGene Holdings' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving EnGene Holdings' quantitative information. For example, before you start analyzing numbers published by EnGene accountants, it's essential to understand EnGene Holdings' liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.

EnGene Holdings Workforce Analysis

Traditionally, organizations such as EnGene Holdings use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare EnGene Holdings within its industry.

EnGene Holdings Manpower Efficiency

Return on EnGene Holdings Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee984.7K
Net Loss Per Executive3.2M
Working Capital Per Employee4.2M
Working Capital Per Executive13.7M

Other Information on Investing in EnGene Etf

EnGene Holdings financial ratios help investors to determine whether EnGene Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EnGene with respect to the benefits of owning EnGene Holdings security.